Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
New immunotherapeutic strategy shows promise to fight off infectious biofilms

New immunotherapeutic strategy shows promise to fight off infectious biofilms

Widowed individuals experience a sharper cognitive decline than their married counterparts

Widowed individuals experience a sharper cognitive decline than their married counterparts

Study identifies novel anti-aging targets

Study identifies novel anti-aging targets

Effects of obesity mirror those of aging, study shows

Effects of obesity mirror those of aging, study shows

U.S. medical panel thinks twice about pushing cognitive screening for dementia

U.S. medical panel thinks twice about pushing cognitive screening for dementia

Simple blood test could help identify cardiovascular aging and heart disease risk

Simple blood test could help identify cardiovascular aging and heart disease risk

Supplementing diet with amino acid delays signs of ALS in animal study

Supplementing diet with amino acid delays signs of ALS in animal study

Researchers discover glial cells that control stress response, extend lifespan in worms

Researchers discover glial cells that control stress response, extend lifespan in worms

Two new grants will help researchers to study neurotechnology, drug delivery system

Two new grants will help researchers to study neurotechnology, drug delivery system

Hispanics/Latinos underrepresented in clinical trials for Alzheimer’s disease

Hispanics/Latinos underrepresented in clinical trials for Alzheimer’s disease

Increase in out-of-pocket costs associated with lower adherence to neurologic medications

Increase in out-of-pocket costs associated with lower adherence to neurologic medications

New understanding of neurovascular coupling

New understanding of neurovascular coupling

Environment-cognition associations vary based on genetic risk factor for Alzheimer's

Environment-cognition associations vary based on genetic risk factor for Alzheimer's

Diverse activities are key to maintaining cognitive function throughout adulthood

Diverse activities are key to maintaining cognitive function throughout adulthood

Survey: Majority of Americans strongly support organ and tissue donation for research

Survey: Majority of Americans strongly support organ and tissue donation for research

Study reveals how cells remove misfolded proteins from tissues

Study reveals how cells remove misfolded proteins from tissues

Dementia prevalence falling but the number of cases will double by 2050

Dementia prevalence falling but the number of cases will double by 2050

Fruit flies have a new defense strategy to deal with oxidative stress

Fruit flies have a new defense strategy to deal with oxidative stress

Study uses MRI to probe non-invasively inside a living brain

Study uses MRI to probe non-invasively inside a living brain

Research suggests new approach to block tau pathology in FTLD, Alzheimer's

Research suggests new approach to block tau pathology in FTLD, Alzheimer's

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.